The trial investigates the use of VPA (Valproic Acid) for the treatment of adult patients
with biopsy proven idiopathic focal segmentel glomerulosclerosis (FSGS) or minimal change
VPA used as an add-on to steroids might induce clinical remission in a first category of
patients and potentially reduce the dose of maintenance immunosuppression required to
maintain remission thereafter.
In a second category of patients VPA might allow the reduction or even cessation of
immunosuppression while clinical remission is maintained.